Disease on EC 2.6.1.16 - glutamine-fructose-6-phosphate transaminase (isomerizing)
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Adenocarcinoma
GFPT2-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma.
Adenocarcinoma
High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma.
Adenoviridae Infections
A novel variant of glutamine: fructose-6-phosphate amidotransferase-1 (GFAT1) mRNA is selectively expressed in striated muscle.
Breast Neoplasms
Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Carcinogenesis
GFPT2 promotes metastasis and forms a positive feedback loop with p65 in colorectal cancer.
Carcinoma, Hepatocellular
Characterization of rat hepatoma glucosamine 6-phosphate synthase and its relation to liver and fetal forms.
Carcinoma, Hepatocellular
Comparison of the properties of glucosaminephosphate isomerase (glutamine-forming) from rat liver and a hepatoma.
Carcinoma, Hepatocellular
High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment.
Cardiomegaly
Chronic activation of hexosamine biosynthesis in the heart triggers pathological cardiac remodeling.
choline o-acetyltransferase deficiency
Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up.
Diabetes Complications
cDNA cloning and mapping of a novel subtype of glutamine:fructose-6-phosphate amidotransferase (GFAT2) in human and mouse.
Diabetes Complications
Expression and purification of active human internal His(6)-tagged L-glutamine: D-Fructose-6P amidotransferase I.
Diabetes Complications
Identification of GFAT1-L, a novel splice variant of human glutamine: fructose-6-phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle.
Diabetes Mellitus, Type 2
Common variants in glutamine:fructose-6-phosphate amidotransferase 2 (GFPT2) gene are associated with type 2 diabetes, diabetic nephropathy, and increased GFPT2 mRNA levels.
Diabetes Mellitus, Type 2
Effect of +36T>C in intron 1 on the glutamine: fructose-6-phosphate amidotransferase 1 gene and its contribution to type 2 diabetes in different populations.
Diabetes Mellitus, Type 2
Expression and purification of active human internal His(6)-tagged L-glutamine: D-Fructose-6P amidotransferase I.
Diabetes Mellitus, Type 2
From Lobry de Bruyn to enzyme-catalyzed ammonia channelling: molecular studies of D-glucosamine-6P synthase.
Diabetes Mellitus, Type 2
Glutamine fructose-6-phosphate amidotransferase (GFAT) gene expression and activity in patients with type 2 diabetes: inter-relationships with hyperglycaemia and oxidative stress.
Diabetes Mellitus, Type 2
Glutamine: fructose-6-phosphate amidotransferase (GFAT): homology modelling and designing of new inhibitors using pharmacophore and docking based hierarchical virtual screening protocol.
Diabetes Mellitus, Type 2
Glutamine:fructose-6-phosphate amidotransferase activity in cultured human skeletal muscle cells: relationship to glucose disposal rate in control and non-insulin-dependent diabetes mellitus subjects and regulation by glucose and insulin.
Diabetes Mellitus, Type 2
Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM.
Diabetes Mellitus, Type 2
Structural analysis of human glutamine:fructose-6-phosphate amidotransferase, a key regulator in type 2 diabetes.
Diabetic Angiopathies
Glutamine:fructose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-beta1 and fibronectin expression in mesangial cells.
Diabetic Nephropathies
Common variants in glutamine:fructose-6-phosphate amidotransferase 2 (GFPT2) gene are associated with type 2 diabetes, diabetic nephropathy, and increased GFPT2 mRNA levels.
Diabetic Nephropathies
Glutamine:fructose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-beta1 and fibronectin expression in mesangial cells.
Diabetic Nephropathies
Molecular screening of the human glutamine-fructose-6-phosphate amidotransferase 1 (GFPT1) gene and association studies with diabetes and diabetic nephropathy.
Diabetic Nephropathies
Scrutiny of the glutamine-fructose-6-phosphate transaminase 1 (GFPT1) locus reveals conserved haplotype block structure not associated with diabetic nephropathy.
Esophageal Neoplasms
LncRNA ELFN1-AS1 promotes esophageal cancer progression by up-regulating GFPT1 via sponging miR-183-3p.
Glioblastoma
Correction to: Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1).
Glioblastoma
Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1).
Glioma
Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1).
Glucose Intolerance
Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance.
glutamine-fructose-6-phosphate transaminase (isomerizing) deficiency
Chronic activation of hexosamine biosynthesis in the heart triggers pathological cardiac remodeling.
glutamine-fructose-6-phosphate transaminase (isomerizing) deficiency
Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up.
glutamine-fructose-6-phosphate transaminase (isomerizing) deficiency
Drosophila GFAT1 and GFAT2 enzymes encode obligate developmental functions.
glutamine-fructose-6-phosphate transaminase (isomerizing) deficiency
GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice.
Glycogen Storage Disease Type II
Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).
Hyperglycemia
Glucose catabolic gene mRNA levels in skeletal muscle exhibit non-coordinate expression in hyperglycemic mice.
Hyperglycemia
The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects.
Hyperlipidemias
Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance.
Infections
Molecular docking based screening of G6PS with 1, 5 Benzothiazepine derivates for a potential inhibitor.
Insulin Resistance
Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance.
Insulin Resistance
Cloning and characterization of mouse glutamine:fructose-6-phosphate amidotransferase 2 gene promoter.
Insulin Resistance
Differential effects of GLUT1 or GLUT4 overexpression on hexosamine biosynthesis by muscles of transgenic mice.
Insulin Resistance
Effect of sucrose and saturated-fat diets on mRNA levels of genes limiting muscle fatty acid and glucose supply in rats.
Insulin Resistance
Glutamine fructose-6-phosphate amidotransferase (GFAT) gene expression and activity in patients with type 2 diabetes: inter-relationships with hyperglycaemia and oxidative stress.
Insulin Resistance
Hexosamine biosynthesis pathway flux contributes to insulin resistance via altering membrane phosphatidylinositol 4,5-bisphosphate and cortical filamentous actin.
Insulin Resistance
High-Fat Diet Leads to Reduced Protein O-GlcNAcylation and Mitochondrial Defects Promoting the Development of Alzheimer's Disease Signatures.
Insulin Resistance
Identification of GFAT1-L, a novel splice variant of human glutamine: fructose-6-phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle.
Insulin Resistance
Increased hexosamine pathway flux and high fat feeding are not additive in inducing insulin resistance: evidence for a shared pathway.
Insulin Resistance
Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione.
Insulin Resistance
Molecular characterization, chromosomal location, alternative splicing and polymorphism of porcine GFAT1 gene.
Insulin Resistance
Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase.
Insulin Resistance
New insights into the metabolic regulation of insulin action and insulin resistance: role of glucose and amino acids.
Insulin Resistance
Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance.
Insulin Resistance
Regulation of insulin-stimulated glycogen synthase activity by overexpression of glutamine: fructose-6-phosphate amidotransferase in rat-1 fibroblasts.
Insulin Resistance
Select nutrients, progesterone, and interferon tau affect conceptus metabolism and development.
Iron Deficiencies
Iron Deficiency Reprograms Phosphorylation Signaling and Reduces O-GlcNAc Pathways in Neuronal Cells.
Leukemia L1210
The influence of L-norvalyl-N3-4-methoxyfumaroyl-L-2,3-diaminopropanoic acid, an antifungal agent, on mammalian cells in tissue culture.
Lung Neoplasms
Effects of monophosphoryllipid-A on the immunization of mice with keyhole limpet hemocyanin- and muramyldipeptide-ganglioside Gfpt1 conjugates.
Lymphatic Metastasis
High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer.
Lymphatic Metastasis
Loss of GFAT1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer.
Malaria
Identifying antimalarial compounds targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling.
Malaria
Overexpression of the HECT ubiquitin ligase PfUT prolongs the intraerythrocytic cycle and reduces invasion efficiency of Plasmodium falciparum.
Melanoma
UDP-sugar substrates of HAS3 regulate its O-GlcNAcylation, intracellular traffic, extracellular shedding and correlate with melanoma progression.
Metabolic Syndrome
Lipogenesis is decreased by grape seed proanthocyanidins according to liver proteomics of rats fed a high fat diet.
Muscle Weakness
Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR.
Muscular Diseases
Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).
Muscular Diseases
Novel compound heterozygous GFPT1 mutations in a family with limb-girdle myasthenia with tubular aggregates.
Muscular Diseases
Tubular Aggregates and Cylindrical Spirals Have Distinct Immunohistochemical Signatures.
Muscular Dystrophies
Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).
Muscular Dystrophies, Limb-Girdle
Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).
Myasthenic Syndromes, Congenital
A 3'-UTR mutation creates a microRNA target site in the GFPT1 gene of patients with congenital myasthenic syndrome.
Myasthenic Syndromes, Congenital
Congenital myasthenic syndrome caused by a frameshift insertion mutation in GFPT1.
Myasthenic Syndromes, Congenital
Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations.
Myasthenic Syndromes, Congenital
GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice.
Myasthenic Syndromes, Congenital
Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1).
Myasthenic Syndromes, Congenital
Leukoencephalopathy due to variants in GFPT1-associated congenital myasthenic syndrome.
Myasthenic Syndromes, Congenital
Limb-girdle myasthenia with tubular aggregates associated with novel GFPT1 mutations.
Myasthenic Syndromes, Congenital
Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates.
Myasthenic Syndromes, Congenital
Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR.
Myasthenic Syndromes, Congenital
Mutations in GFPT1-related congenital myasthenic syndromes are associated with synaptic morphological defects and underlie a tubular aggregate myopathy with synaptopathy.
Myasthenic Syndromes, Congenital
Novel compound heterozygous variants in the GFPT1 gene leading to rare limb-girdle congenital myasthenic syndrome with rimmed vacuoles.
Myasthenic Syndromes, Congenital
Phenotype of a limb-girdle congenital myasthenic syndrome patient carrying a GFPT1 mutation.
Myasthenic Syndromes, Congenital
Trouble at the junction: When myopathy and myasthenia overlap.
Myasthenic Syndromes, Congenital
Tubular Aggregates and Cylindrical Spirals Have Distinct Immunohistochemical Signatures.
Mycoses
Functional co-evolutionary study of glucosamine-6-phosphate synthase in mycoses causing fungi.
Mycoses
Purification to homogeneity of Candida albicans glucosamine-6-phosphate synthase overexpressed in Escherichia coli.
Myocardial Infarction
Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure.
Neoplasm Metastasis
High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer.
Neoplasm Metastasis
High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma.
Neoplasm Metastasis
Loss of GFAT1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer.
Neoplasms
Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Neoplasms
Effects of monophosphoryllipid-A on the immunization of mice with keyhole limpet hemocyanin- and muramyldipeptide-ganglioside Gfpt1 conjugates.
Neoplasms
Emerging Anticancer Activity of Candidal Glucoseamine-6-Phosphate Synthase Inhibitors upon Nanoparticle-Mediated Delivery.
Neoplasms
Enhanced hexosamine metabolism drives metabolic and signaling networks involving hyaluronan production and O-GlcNAcylation to exacerbate breast cancer.
Neoplasms
High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma.
Neoplasms
High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma.
Neoplasms
Hyaluronan Production Regulates Metabolic and Cancer Stem-like Properties of Breast Cancer Cells via Hexosamine Biosynthetic Pathway-coupled HIF-1 Signaling.
Neoplasms
Loss of GFAT1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer.
Neuromuscular Junction Diseases
Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations.
Obesity
Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance.
Obesity
The -913 G/A glutamine:fructose-6-phosphate aminotransferase gene polymorphism is associated with measures of obesity and intramyocellular lipid content in nondiabetic subjects.
Pancreatic Neoplasms
2-Deoxy-d-glucose increases GFAT1 phosphorylation resulting in endoplasmic reticulum-related apoptosis via disruption of protein N-glycosylation in pancreatic cancer cells.
Pancreatic Neoplasms
High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer.
Pulmonary Fibrosis
Elevation of glucosamine 6-phosphate synthetase activity in bleomycin-induced pulmonary fibrosis in hamsters.
Pulmonary Fibrosis
Peplomycin sulfate and pulmonary fibrosis: hydroxyproline, uronic acid, proline hydroxylase and glucosamine 6-phosphate synthetase in lungs of hamsters treated with peplomycin.
Small Cell Lung Carcinoma
Effects of monophosphoryllipid-A on the immunization of mice with keyhole limpet hemocyanin- and muramyldipeptide-ganglioside Gfpt1 conjugates.
Starvation
mTORC2 modulates the amplitude and duration of GFAT1 Ser243 phosphorylation to maintain flux through the hexosamine pathway during starvation.
Stomach Neoplasms
Loss of GFAT1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer.
Stomach Ulcer
Aminosugars in cases of gastric ulcers. II. The activity of L-glutamine: D-fructose-6-phosphate aminotransferase (E. C. 2.6.1.16) in human gastric mucous membrane.
Triple Negative Breast Neoplasms
Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
html completed